Developing blockbuster drugs as anchors in their portfolios is a key commercial goal for pharmaceutical companies. However, it’s no easy feat. The landscape is highly competitive, some therapeutic areas are crowded, and market access is increasingly complex.
Despite these challenges, some drugs not only make it to market but also become massive, even “megablockbuster” successes. This occurs more often than you might think. According to Evaluate Pharma, nearly 39% of the drugs approved by the FDA from 2014 to 2023 are on track to generate over $1 billion each at their sales peak. So, what’s the secret? How do they achieve this?
Get the answers in this eBook. Learn about the role that indications play, the typical timeline to reach blockbuster status, and the advantages of developing drugs internally versus outsourcing.
Get insights on:
- The multiple routes to building a blockbuster.
- Whether indication expansion drives revenue growth.
- Winning therapeutic areas.
- How long it takes to surpass $1bn, $5bn, and even $10bn.
